Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism
申请人:Lawrence Daniel A.
公开号:US20100137194A1
公开(公告)日:2010-06-03
The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.
PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM
申请人:THE REGENTS OF THE UNIVERSITY OF MICHIGAN
公开号:US20160009748A1
公开(公告)日:2016-01-14
The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.
Oxygen Heterocycles. A New Isoflavanone from Sophora japonica, L.
作者:HIROSHI SUGINOME
DOI:10.1021/jo01093a008
日期:1959.11
Über die Konstitution der Maxima-Substanz C
作者:S. Rangaswami、B. V. Rama Sastry
DOI:10.1002/ardp.19592920403
日期:——
Methods and compositions for treating metabolic disorders
申请人:Mootha Vamsi Krishna
公开号:US20090143279A1
公开(公告)日:2009-06-04
The present invention provides methods of treating of disorders characterized by defective mitochondrial activity. In particular compounds of the present invention can be used in the treatment metabolic diseases and neurodegenerative diseases. The methods are also useful to increase oxidative phosphorylation or to decrease reactive oxygen species (ROS) production in a subject in need thereof.